Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DOG2, After your first post I suggested you produce some TA to support your claim, but you did not or were unable to. FYI, the biotec index (.NBI), currently at 708, has very strong support at 650, and it hasn't been down to 400 for since 07/02 and then with a strong bounce. What are you basing your claim on? You're not even very talented as a basher.
dog dog, maybe you've been a "snoop" here for a while, but you only registered here today, and you have zero credibility.
Why don't you back up your assertions with some TA of the Biotech index chart? Your claim sounds like it came from one of those stock tout mailings that come in the mail so often.
Have you shorted the biotech index? If you've watched the biotechs for a while, you know that not every stock runs with the herd. Most of the smaller companies are news driven, not sector driven. If you sense fire in the theatre, feel free to run out!
arnold, borrowing 4 mil at CYGX's current financial position would be like an individual with no credit background borrowing a large sum on a credit card...you're going to pay a heavy interest rate. Payments come due at specific times, and for a company with no reliable income, it becomes very dicey to borrow money, not to mention the bad press if there is a default on a loan. Issuing additional shares, on the other hand, does not require payments to a lender, and the shares in the "bank" are very versatile. Thus it's a safer move to issue shares than to borrow.
1900 @ .62, which is my cost basis for my first 100K shares.
If this were 1999 and CYGX was a dot-com, we'd be making skooby's PPS calls look modest, but alas it's no longer 1999. Now-a-days, a company has to show the beef (ie revenues, real or imminent) to appreciate much. I don't look for any move until phase II of the herpes trials shows some positive results. But we are building a massive base to grow on. When we do take off, it should be spectacular. Meantime, lots of interesting stuff showing up in the field: http://www.nasdaq.com//asp/quotes_news.asp?logopath=http%3a%2f%2fcontent.nasdaq.com%2flogos%2fCRGN.G...
I don't see Chen's article listed in the current Biochem. Journal....http://pubs.acs.org/journals/bichaw/index.html#TOP
Most current cancer treatments don't even approach being a "cure". They instead look at 2 or 5 or 10 year survival rates. The various kinds of chemotherapies out there are poisions that you try to take enough of to suppress the cancer cells without killing the host. Radiation trys to fry enough of the tumor or your bone marrow to shrink the cancer without causing too much damage to the surrounding healthy tissue. Surgical approaches try to cut out enough healthy tissue around the tumor to prevent it from spreading. All are dismal approaches that make many doctors, drug firms, and equipment makers very wealthy, because sick people will pay anything to live a while longer. CYGX's approach probably will have no side effects, and will probably be repeatable as needed to keep a cancer at bay indefinitely. Happy day!
Tat...lets go to the final step. What's the cause of aging?
Is it damaged DNA or RNA? Can CYGX's technology play any role in stopping the aging process? Looks like everything else is as good as cured!
neo...see the press release dated Aug 5th. This is what this collaboration is all about.
Skooby, The talk is Tuesday, not Monday. EOM.
Skoob, my big question is, how much of the farm does cygx have to give away (sell) to get the 15 million? With our current 80 or so mil market cap, raising 15 mil by private placement would cause considerable dilution. The non-dilutional approach to fund raising is to sell rights to certain technologies under development, as we have done for phanuel. Which way do you think we are headed?
Thalio, you have discussed in considerable detail the workings of anti-sense on viral attacks. Would you care to expound on the mechanism of action against cancers? Since cancer is basically out of control cell division, how does anti-sense address this? Do you see the treatment approach as a possible injection into a tumor mass, or an attachment to an isotope that concentrates itself in rapidly dividing cells? TIA.
Peach...take a look at #176 & 182. Both contain lots of good information. Also, any of Thalio's posts. And the company's webb page and press releases. Finally, look closely at the credentials of the principal employees.
R-rock, in general I agree with you, but there are some significant exceptions, eg when a start-up has a very unique technology but is faced with a longer ramp-up. CYGX is one example, and I've reduced my EDIG shares to 25K, so I can load up on the latter.
bb, thanks for the link. Looks like Dr Chen is speaking at the workshop, last presentation of the day, on Tues., Nov. 11. Unfortunate timing, since many attendees will probably have left the room by then.
Workshop only is $199. Contributions anyone? I'm rich after we hit $10, poor until then. john
Can anyone recall the dates of the RNA meeting in San Diego in which Dr Chen will present his paper? The press release last June doesn't give the dates, just says November. Since I live here, thought it'd be fun to try to get in, so I could see the response to the paper.
How do Freetrade and Ameritrade compare as far as executions, streaming RTQ's and charts are concerned? I've been with Fidelity for many years and some of my recent CYGX purchases cose me several hundred $. I want to move my account(s) over, but I also don't want my trading ability to be held up for weeks while the transfer is being made. I do have a Scottrade office 4-5 miles from my home, but the other two would have to be done electronically, I guess.
There are many different rhino viruses that cause the common cold, and nature is inventing new ones all the time, so keeping up with the latest bug going around would take some fast footwork, to say the least. Putting out one or several flu "silencers" a year would be much more doable. Inhalation
would be a great delivery mode.
Or get a product on the market in China and India and see rev's much sooner than in the USA.
Thanks for the recap. Very helpful.
Anyone know if the audiocast of this conference is open to the public, or only to managers? If available, who's planning to listen? It should give CYGX some valuable exposure.
"Our" refers to CYGX. As a shareholder, I'm a partial owner of the company.
Thalio, How did you learn about our application for patents on ssDNA based antibiotics? Was there a press release, or was this a private communication? TIA. John
grrdvm1, I don't think a move up a penny at the open constitutes a gap. At least I hope so. Interesting stuff on Bunker. The rich just get richer. This will be one of his best bets ever. John
Did we gap up today? I hope we don't have any gaps to fill.
So the actual # of shares available for trading must be fairly low. Is Hunt part of Phanuel?
Speaking of holding onto your shares, how many are actually in the float? Phanuel must be holding onto a big wad, and they likely won't be trading them anytime soon. Company insiders may be selling some going forward, just to pay the mortgage or other living expenses. The last annual report I think said there were 60 mil shares outstanding(and 150mil approved), but I bet the actual float is much less than 60 mil. Does anyone have any numbers?
Thanks, Bull, I registered for it. EOM
Can anyone here reference a site that has free RTQ's? TIA
Thanks, Doxi. Where did you hear about the Phanuel webb-site?
Please post a link when it's up.
texguy, what can you tell us about Phanuel? Can your son provide any more info? Very important to shareholders, since Phanuel controls a huge portion of the foreign HSV potion sales. Who are the principals? How many shares do they control? What pre-existing connections to China and India do they have? What kind of business talent do they contain? Any info would be of interest. TIA.
grrdvm...are you still in EDIG? I've been selling into EDIG's recent rally to raise the funds to buy more CYGX. Have held EDIG since 1999, and am now down to 30K shares. Obviously a humongous mistake, and now I may be selling on the way up, but I think the intermediate and long term for CYGX is much better than EDIG. I was a deer in the headlights on EDIG mainly because of the hype on RB...the next big event was always just aroung the corner sort of thing, and that's why I'd prefer to see this board free from hype, particularly wild price speculation. I've unintentionally gotten several doctors here at work into the stock( they're orthopods, not cell-types) just because they've glanced at my computer screen and started asking questions. john
Sko...By "Big Board", are you referring to the NYSE? Or do you really mean the NASDAQ? If you are referrong to the NAS, have you looked at the listing requirements? There's a link on the home page. A minimum bid of $5 for 90 days is required for listing. Do you really think that is doable by years end?
I've seen several other boards where the price is over-hyped, as I think you are doing, and all it does is attract bashers and other low-life types. Why not let the share price speak for itself?
THALIO, THE ABSTRACT TO THE PAPER SAID IT WHACKED 76% OF THE THINGYS. CAN THAT BE CALLED A "CURE", OR IS IT MORE LIKE ALL THE OTHER SO-CALLED BIG C CURES THAT USUALLY JUST POSTPONE THE INEVITABLE? IN THE CASE OF LUNG CA, COULD THE DELIVERY SYSTEM BE AN AEROSOL? TIA
thalio, any comments on last Friday's PR?
If you've expanded your realms of DD so far, what else have you discovered about Phanuel? And there are a zillion BB companies out there whose managerial pronouncements have to be taken with a grain of salt. CYGX's science seems solid, but the money is in the execution. Lots of bright guys have failed in the business side of things. I certainly will see what I can find on Phanuel, but I know there are better sleuthers on this board than myself.
Has anyone done any research on Phanuel? Since they now control distribution rights to 40% of the world's population for CYGX's herpes treatment, I hope they're up to the task. I'm curious as to who are the principals, their underlying connection to CYGX, and why they're domiciled in the USVI. Any references would be useful to all, IMO.
Thalio, thanks for the additional info. Does sound very good.
Re the China distribution contract...any guesses how much up front they would have received for the rights to sell the stuff to over a billion people? How strict is the Chinese equivalent of our FDA as far as getting a new product to market?
Thanks, thalio. I'm surrounded by cell geeks out here in LaJolla, CA, but I'm in orthopedics myself. Would be interested in learning more of the difference between ssRNA and ssDNA. I haven't read CYGX's patent, because I probably would not understand much of it. If you have, can you shed any light on just what it covers? Does it have a lock on intracellular ssDNA as an RNA silencer? TIA.
Thalio, I'm sure they are familiar with Anylnam...the question is how the two technologies compare. Page 7 of the referenced article says that dsRNA is orders of magnitude more effective than ssRNA. Did you get any response on this issue?
Logging off for now. Will check back tomorrow.